# Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Source: https://onco.cc/trials/nct05371093/  
OnCo record `nct05371093` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine in follicular lymphoma, run by Kite, A Gilead Company, active and no longer recruiting.

## Summary

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma is a phase 3 interventional study registered as NCT05371093 by Kite, A Gilead Company, with 231 participants enrolled, started 2022-09-22 and due to reach its primary completion in 2030-10. Interventions recorded: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab. Conditions listed: Relapsed/Refractory Follicular Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05371093
- Phase: 3
- Setting: A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma
- Sponsor: Kite, A Gilead Company
- Enrolled: 231

## Sources

- ClinicalTrials.gov NCT05371093: https://clinicaltrials.gov/study/NCT05371093

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct05371093.json